

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

CHANGE OF NAME OF PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE AND REGISTERED OFFICE IN THE CAYMAN ISLANDS

The board of directors (the “**Board**”) of Cutia Therapeutics (the “**Company**”) hereby announces that the name of the Company’s principal share registrar and transfer office and registered office in the Cayman Islands has been changed from “Harneys Fiduciary (Cayman) Limited” to “Ascentium (Cayman) Limited” with effect from 17 April 2026.

The address of the Company’s principal share registrar and transfer office and registered office in the Cayman Islands remains unchanged.

By order of the Board

Cutia Therapeutics

Zhang Lele

Chief Executive Officer and Executive Director

Hong Kong, 27 April 2026

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.